Tirzepatide's dual receptor action — what it means for weight loss

Why two receptors instead of one?

A common assumption is that GIP and GLP-1 do the same job through different routes. They do not. GLP-1 receptor agonists (semaglutide being the most widely known) slow the rate at which the stomach empties, blunt hunger signals in the brain, and prompt the pancreas to release insulin in a glucose-dependent way. GIP, by contrast, acts partly on fat tissue and appears to modulate how the body stores and mobilises energy. Crucially, when both receptors are activated together, the appetite-suppressing effect is larger than either achieves alone. This synergy is the scientific reason tirzepatide's trial outcomes exceeded those of single-pathway medicines in head-to-head data.

The SURMOUNT-5 trial, published in 2025, ran tirzepatide directly against semaglutide 2.4 mg in adults with obesity but without diabetes. Tirzepatide produced greater average weight reduction. That comparison matters because it reflects the real clinical question many people face: one dual agonist against the most established GLP-1 option. You can read more about the broader evidence on the tirzepatide overview page, and the specific detail of whether tirzepatide qualifies as a dual agonist is covered on our dedicated dual-agonist explainer.

What the dual mechanism does not mean

A bigger mechanism does not automatically mean a better fit. Two things are worth being direct about. First, the GI side-effect profile (nausea, loose stools, constipation, bloating, occasional vomiting) is common to both GLP-1 and dual-agonist medicines. Tirzepatide's tolerability data are generally comparable to semaglutide's, but neither is free of these effects, particularly in the first weeks after starting or after a dose increase. Symptoms tend to settle as the body adjusts, but they are real and worth factoring in before starting.

Second, the dual pathway is not a shortcut around the rest of the clinical picture. Tirzepatide is licensed for adults with a BMI of 30 or above (or 27-plus with a qualifying condition such as hypertension, type 2 diabetes, or obstructive sleep apnoea). Lower thresholds apply for some ethnic backgrounds under UK guidance. Neither the mechanism nor the trial statistics remove the need for individual prescriber assessment. The NICE appraisal of tirzepatide (TA1026) sets out the eligibility criteria the NHS uses; private prescribing follows the licensed indications in the SmPC. If you are comparing options and want a sense of the cost context, the Mounjaro cost page explains what to look for in a transparent price.

How the decision actually lands

Most people reading this page are weighing up one of a few things: whether to try tirzepatide rather than a GLP-1-only medicine, whether the science justifies the step, or whether the results in trials translate to real-world use. Those are reasonable questions, and the honest answer is that the dual mechanism does appear to drive measurably better average outcomes, but individual response varies, and no trial average is a personal prediction.

Prescribers at nume look at your full health picture: current weight, relevant conditions, medicines you already take (tirzepatide can reduce absorption of oral contraceptives during the first four weeks of treatment and after each dose increase, so a back-up method is advisable during that window), and your own goals and preferences. Mounjaro is sold in the UK as a once-weekly injection pen, starting at 2.5 mg (a dose chosen to help your system adjust, not to produce weight loss at that point) and titrated upward by the prescriber from there. You can read the broader story of Mounjaro as a treatment on the Mounjaro page, and explore how the tirzepatide options compare, including tirzepatide l and the other available formulations, on the Mounjaro or tirzepatide comparison page.

The weight-loss treatments overview covers the full range of licensed options if you are still at the stage of deciding which medicine to ask about. Either way, the right path starts with a clinical conversation rather than a mechanism comparison on its own. If you'd like to speak to our prescribers about whether tirzepatide is appropriate for you, start your free consultation.